221 related articles for article (PubMed ID: 27672333)
21. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
Emambux S; Italiano A
Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.
López-Álvarez M; González-Aguilera C; Moura DS; Sánchez-Bustos P; Mondaza-Hernández JL; Martín-Ruiz M; Renshaw M; Ramos R; Castilla C; Blanco-Alcaina E; Hindi N; Martín-Broto J
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614121
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of peripheral blood markers in soft tissue sarcoma patients treated with eribulin.
Ishihara S; Ogura K; Maejima A; Shimoi T; Sudo K; Kojima Y; Fukushima S; Osaki S; Kobayashi E; Iwata S; Matsui Y; Yonemori K; Kawai A
Jpn J Clin Oncol; 2023 Jun; 53(6):494-500. PubMed ID: 36989466
[TBL] [Abstract][Full Text] [Related]
24. Eribulin: a novel cytotoxic chemotherapy agent.
Preston JN; Trivedi MV
Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
[TBL] [Abstract][Full Text] [Related]
25. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
26. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.
In GK; Hu JS; Tseng WW
Ther Adv Med Oncol; 2017 Aug; 9(8):533-550. PubMed ID: 28794805
[TBL] [Abstract][Full Text] [Related]
27. Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and Implications of New Biomarkers.
Nakamura H; Takada K; Emori M; Hayasaka N; Sugita S
Intern Med; 2022 Dec; 61(23):3617-3621. PubMed ID: 35527027
[TBL] [Abstract][Full Text] [Related]
28. Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience.
Steinbrecher O; Brodowicz T; Raderer M; Scharrer A; Fabsits J; Lamm W
Oncology; 2023; 101(2):89-95. PubMed ID: 36273457
[TBL] [Abstract][Full Text] [Related]
29. Eribulin in non-small cell lung cancer: challenges and potential strategies.
Swami U; Shah U; Goel S
Expert Opin Investig Drugs; 2017 Apr; 26(4):495-508. PubMed ID: 28161993
[TBL] [Abstract][Full Text] [Related]
30. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
Aseyev O; Ribeiro JM; Cardoso F
Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
[TBL] [Abstract][Full Text] [Related]
31. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
32. The importance of treating by histological subtype in advanced soft tissue sarcoma.
Martín Broto J; Le Cesne A; Reichardt P
Future Oncol; 2017 Jan; 13(1s):23-31. PubMed ID: 27918201
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy With Eribulin Following Potentially Curative Surgery in Patients With Localized Liposarcoma.
Steinbrecher O; Brodowicz T; Popov P; Lamm W
In Vivo; 2024; 38(1):385-389. PubMed ID: 38148100
[TBL] [Abstract][Full Text] [Related]
34. Uterine leiomyosarcoma well-controlled with eribulin mesylate.
Fujimoto E; Takehara K; Tanaka T; Yokoyama T; Tomono K; Okazawa-Sakai M; Okame S; Sugawara Y; Teramoto N
Int Cancer Conf J; 2019 Jan; 8(1):33-38. PubMed ID: 31149544
[TBL] [Abstract][Full Text] [Related]
35. Eribulin mesylate in the treatment of metastatic breast cancer.
Jain S; Cigler T
Biologics; 2012; 6():21-9. PubMed ID: 22291464
[TBL] [Abstract][Full Text] [Related]
36. Contemporary management of metastatic soft tissue sarcoma.
Bui NQ; Wang DS; Hiniker SM
Curr Probl Cancer; 2019 Aug; 43(4):289-299. PubMed ID: 31248634
[TBL] [Abstract][Full Text] [Related]
37. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
38. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
O'Shaughnessy J; Kaklamani V; Kalinsky K
Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
[TBL] [Abstract][Full Text] [Related]
39. Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.
Menis J; Twelves C
Breast Cancer (Dove Med Press); 2011 Aug; 3():101-11. PubMed ID: 24367180
[TBL] [Abstract][Full Text] [Related]
40. Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?
Escudero J; Heredia-Soto V; Wang Y; Ruiz P; Hu Y; Gallego A; Pozo-Kreilinger JJ; Martinez-Marin V; Berjon A; Ortiz-Cruz E; Bernabeu D; Feliu J; Tang J; Redondo A; Mendiola M
Cancer Cell Int; 2021 Dec; 21(1):646. PubMed ID: 34863177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]